Fiche publication
Date publication
mai 2025
Journal
NPJ precision oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MALOUF Gabriel
Tous les auteurs :
Lu X, Vano YA, Su X, Verkarre V, Sun CM, Cheng W, Xu L, Yan F, Kotti S, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG
Lien Pubmed
Résumé
In metastatic clear-cell renal cell carcinoma (mccRCC), choosing between immuno-oncology (IO) combinations and IO plus anti-VEGF therapies is uncertain. The BIONIKK trial revealed that ipilimumab plus nivolumab (Ipi/Nivo) achieved a 70% objective response rate in angiogenic cluster1/2 versus 41% in cluster4/5, which featured T-effector/cell-cycle signatures (p = 0.048). Complete responses were exclusively observed in cluster1/2 (p = 0.012), with longer progression-free survival (p = 0.014). Ipi/Nivo may particularly benefit angiogenic mccRCC, supporting molecular subtype-based treatment strategies.
Référence
NPJ Precis Oncol. 2025 05 8;9(1):134
